-DOCSTART- -X- O
Background -X- _ O
Viral -X- _ B-Patient
respiratory -X- _ I-Patient
infections -X- _ I-Patient
are -X- _ O
associated -X- _ O
with -X- _ O
significant -X- _ O
morbidity -X- _ O
and -X- _ O
mortality. -X- _ O
Many -X- _ O
new -X- _ O
aetiological -X- _ O
agents -X- _ O
have -X- _ O
been -X- _ O
described -X- _ O
recently. -X- _ O
Objectives -X- _ O
We -X- _ O
looked -X- _ O
for -X- _ O
respiratory -X- _ B-Patient
viruses -X- _ I-Patient
in -X- _ O
a -X- _ O
population‐based -X- _ B-Patient
sample -X- _ I-Patient
of -X- _ I-Patient
healthy -X- _ I-Patient
adults -X- _ I-Patient
with -X- _ I-Patient
influenza‐like -X- _ I-Patient
illness -X- _ I-Patient
( -X- _ I-Patient
ILI -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
We -X- _ O
investigated -X- _ O
host -X- _ O
and -X- _ O
spatio‐temporal -X- _ O
associations -X- _ O
with -X- _ O
virus -X- _ O
isolation -X- _ O
and -X- _ O
host -X- _ O
, -X- _ O
spatio‐temporal -X- _ O
and -X- _ O
virus -X- _ O
associations -X- _ O
with -X- _ O
self‐reported -X- _ O
symptoms. -X- _ O
Patients -X- _ O
/ -X- _ O
Methods -X- _ O
We -X- _ O
recruited -X- _ O
586 -X- _ B-Patient
participants -X- _ I-Patient
experiencing -X- _ I-Patient
651 -X- _ I-Patient
illness -X- _ I-Patient
episodes -X- _ I-Patient
from -X- _ O
a -X- _ O
population -X- _ O
of -X- _ O
healthy -X- _ O
adults -X- _ O
enrolled -X- _ O
in -X- _ O
an -X- _ O
influenza -X- _ O
vaccine -X- _ O
effectiveness -X- _ O
trial. -X- _ O
At -X- _ O
ILI -X- _ O
assessment -X- _ O
visits -X- _ O
, -X- _ O
a -X- _ O
respiratory -X- _ O
swab -X- _ O
was -X- _ O
collected -X- _ O
and -X- _ O
tested -X- _ O
for -X- _ O
viruses -X- _ O
using -X- _ O
a -X- _ O
combination -X- _ O
of -X- _ O
polymerase -X- _ O
chain -X- _ O
reaction -X- _ O
( -X- _ O
PCR -X- _ O
) -X- _ O
assays. -X- _ O
Participants -X- _ O
also -X- _ O
completed -X- _ O
a -X- _ O
questionnaire -X- _ O
detailing -X- _ O
their -X- _ O
clinical -X- _ O
course -X- _ O
in -X- _ O
336 -X- _ O
episodes. -X- _ O
Results -X- _ O
Of -X- _ B-Outcome
643 -X- _ I-Outcome
samples -X- _ I-Outcome
analysed -X- _ I-Outcome
, -X- _ I-Outcome
a -X- _ I-Outcome
virus -X- _ I-Outcome
was -X- _ I-Outcome
identified -X- _ I-Outcome
in -X- _ I-Outcome
44 -X- _ I-Outcome
% -X- _ I-Outcome
. -X- _ I-Outcome
Half -X- _ I-Outcome
were -X- _ I-Outcome
picornaviruses -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
influenza -X- _ I-Outcome
and -X- _ I-Outcome
coronaviruses -X- _ I-Outcome
the -X- _ I-Outcome
next -X- _ I-Outcome
most -X- _ I-Outcome
common. -X- _ I-Outcome
Individuals -X- _ I-Outcome
with -X- _ I-Outcome
influenza -X- _ I-Outcome
were -X- _ I-Outcome
significantly -X- _ I-Outcome
less -X- _ I-Outcome
likely -X- _ I-Outcome
to -X- _ I-Outcome
have -X- _ I-Outcome
been -X- _ I-Outcome
immunised -X- _ I-Outcome
than -X- _ I-Outcome
the -X- _ I-Outcome
reference -X- _ I-Outcome
( -X- _ I-Outcome
virus -X- _ I-Outcome
negative -X- _ I-Outcome
) -X- _ I-Outcome
population -X- _ I-Outcome
( -X- _ I-Outcome
OR -X- _ I-Outcome
= -X- _ I-Outcome
0·52 -X- _ I-Outcome
( -X- _ I-Outcome
0·31 -X- _ I-Outcome
, -X- _ I-Outcome
0·87 -X- _ I-Outcome
) -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0·01 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
The -X- _ I-Outcome
mean -X- _ I-Outcome
symptom -X- _ I-Outcome
score -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
) -X- _ I-Outcome
reported -X- _ I-Outcome
by -X- _ I-Outcome
individuals -X- _ I-Outcome
with -X- _ I-Outcome
influenza -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
than -X- _ I-Outcome
in -X- _ I-Outcome
all -X- _ I-Outcome
other -X- _ I-Outcome
episodes -X- _ I-Outcome
[ -X- _ I-Outcome
Influenza -X- _ I-Outcome
: -X- _ I-Outcome
10·2 -X- _ I-Outcome
( -X- _ I-Outcome
9·4 -X- _ I-Outcome
, -X- _ I-Outcome
10·9 -X- _ I-Outcome
) -X- _ I-Outcome
; -X- _ I-Outcome
Other -X- _ I-Outcome
: -X- _ I-Outcome
7·4 -X- _ I-Outcome
( -X- _ I-Outcome
7·2 -X- _ I-Outcome
, -X- _ I-Outcome
7·7 -X- _ I-Outcome
) -X- _ I-Outcome
; -X- _ I-Outcome
Difference -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
) -X- _ I-Outcome
: -X- _ I-Outcome
2·5 -X- _ I-Outcome
( -X- _ I-Outcome
1·5 -X- _ I-Outcome
, -X- _ I-Outcome
3·5 -X- _ I-Outcome
) -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
0·001 -X- _ I-Outcome
] -X- _ I-Outcome
. -X- _ I-Outcome
In -X- _ I-Outcome
an -X- _ I-Outcome
analysis -X- _ I-Outcome
restricted -X- _ I-Outcome
to -X- _ I-Outcome
influenza‐positive -X- _ I-Outcome
cases -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
symptom -X- _ I-Outcome
score -X- _ I-Outcome
was -X- _ I-Outcome
not -X- _ I-Outcome
attenuated -X- _ I-Outcome
by -X- _ I-Outcome
vaccination. -X- _ I-Outcome
Conclusions -X- _ O
Our -X- _ O
findings -X- _ O
indicate -X- _ O
that -X- _ O
a -X- _ B-Outcome
greater -X- _ I-Outcome
number -X- _ I-Outcome
of -X- _ I-Outcome
symptoms -X- _ I-Outcome
are -X- _ I-Outcome
displayed -X- _ I-Outcome
by -X- _ I-Outcome
individuals -X- _ I-Outcome
presenting -X- _ I-Outcome
with -X- _ I-Outcome
influenza -X- _ I-Outcome
confirmed -X- _ I-Outcome
ILI -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ I-Outcome
other -X- _ I-Outcome
agents -X- _ I-Outcome
that -X- _ I-Outcome
cause -X- _ I-Outcome
ILI. -X- _ I-Outcome
While -X- _ O
influenza -X- _ O
vaccination -X- _ O
reduced -X- _ O
the -X- _ O
probability -X- _ O
of -X- _ O
influenza -X- _ O
virus -X- _ O
detection -X- _ O
, -X- _ O
symptom -X- _ O
score -X- _ O
for -X- _ O
influenza‐positive -X- _ O
ILI -X- _ O
was -X- _ O
not -X- _ O
attenuated -X- _ O
. -X- _ O

